Trials / Completed
CompletedNCT02866942
Safety of Nasal Influenza Immunisation in Children With Asthma
Safety of Nasal Influenza Immunisation in Children With Asthma - The SNIFFLE-4 Study
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 479 (actual)
- Sponsor
- Imperial College London · Academic / Other
- Sex
- All
- Age
- 2 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
A new influenza vaccine, known as LAIV (Live Attenuated Intranasal Vaccine) has recently been approved by a number of licensing boards and is given by a spray into the nose. In the United Kingdom (UK), the vaccine has been demonstrated to be highly effective against influenza infection. Further, despite concerns that LAIV can cause wheezing in children under age 2 years, the previous SNIFFLE studies have demonstrated it to be safe in children over 2 years with mild-moderate asthma. The objective of this multicentre study is to further assess the safety of intranasal LAIV in children with asthma and recurrent wheeze, including those with severe symptoms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Administration of Live attenuated influenza vaccine (LAIV) |
Timeline
- Start date
- 2016-10-01
- Primary completion
- 2017-03-01
- Completion
- 2017-03-01
- First posted
- 2016-08-15
- Last updated
- 2019-05-10
- Results posted
- 2019-04-26
Source: ClinicalTrials.gov record NCT02866942. Inclusion in this directory is not an endorsement.